Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 13/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 8/20 | 0.55 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.46 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 1/20 | 0.45 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.45 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.45 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2784498 | 0.98 | OPRL1 (1.00) | OPRL1OPRM1OPRK1CYP2D6CYP2C19 | |
| SCHEMBL4352646 | 0.98 | OPRL1 (0.97) | OPRL1OPRM1OPRK1MBTD1L3MBTL3 | |
| Hydrochloric Acid SCHEMBL11077198 | 0.97 | OPRL1 (0.97) | OPRL1OPRM1OPRK1MBTD1L3MBTL3 | |
| Hydrochloric Acid SCHEMBL11078593 | 0.95 | OPRL1 (0.94) | OPRL1OPRM1OPRK1MBTD1L3MBTL3 | |
| Hydrochloric Acid SCHEMBL11075754 | 0.84 | OPRL1 (1.00) | OPRL1OPRM1OPRK1 | |
| SCHEMBL11061930 | 0.80 | OPRL1 (0.67) | OPRL1OPRM1CYP2D6CYP2C19MBTD1 | |
| SCHEMBL2779771 | 0.77 | OPRL1 (0.60) | OPRL1OPRM1CYP2D6 | |
| Hydrochloric Acid SCHEMBL2781838 | 0.76 | OPRL1 (0.61) | OPRL1OPRM1CYP2D6 | |
| SCHEMBL2782210 | 0.75 | OPRL1 (0.78) | OPRL1OPRM1OPRK1 | |
| SCHEMBL4562996 | 0.75 | OPRL1 (0.60) | OPRL1OPRM1OPRK1CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1560823-A1 | 4-SUBSTITUTED 1-AMINOCYCLOHEXANE DERIVATIVES FOR UTILIZATION AS ORL1-RECEPTOR AND MU-OPIATE RECEPTOR LIGANDS | Grünenthal GmbH (DE) | 2005-08-10 | — | — | EP | claimed |
| WO-2004043949-A1 | 4-SUBSTITUTED 1-AMINOCYCLOHEXANE DERIVATIVES FOR UTILIZATION AS ORL1-RECEPTOR AND MU-OPIATE RECEPTOR LIGANDS | Grünenthal GmbH (DE) | 2004-05-27 | — | — | WO | claimed |
| US-7759385-B2 | 4-substituted 1-aminocyclohexane compounds for utilization as ORL1-receptor and mu-opiate receptor ligands | GRUENENTHAL GMBH (DE) | 2010-07-20 | — | — | US | disclosed |
| US-7759385-B2 | 4-substituted 1-aminocyclohexane compounds for utilization as ORL1-receptor and mu-opiate receptor ligands | GRUENENTHAL GMBH (DE) | 2010-07-20 | — | — | US | disclosed |
| US-7759385-B2 | 4-substituted 1-aminocyclohexane compounds for utilization as ORL1-receptor and mu-opiate receptor ligands | GRUENENTHAL GMBH (DE) | 2010-07-20 | — | — | US | disclosed |
| EP-1560823-B1 | 4-SUBSTITUTED 1-AMINOCYCLOHEXANE DERIVATIVES FOR UTILIZATION AS ORL1-RECEPTOR AND MU-OPIATE RECEPTOR LIGANDS | GRUENENTHAL GMBH (DE) | 2008-07-09 | — | — | EP | disclosed |
| US-20050277674-A1 | 4-substituted 1-aminocyclohexane compounds for utilization as ORL1-receptor and mu-opiate receptor ligands | GRUENENTHAL GMBH (DE) | 2005-12-15 | — | — | US | disclosed |
| EP-1560823-A1 | 4-SUBSTITUTED 1-AMINOCYCLOHEXANE DERIVATIVES FOR UTILIZATION AS ORL1-RECEPTOR AND MU-OPIATE RECEPTOR LIGANDS | Grünenthal GmbH (DE) | 2005-08-10 | — | — | EP | disclosed |
| WO-2004043949-A1 | 4-SUBSTITUTED 1-AMINOCYCLOHEXANE DERIVATIVES FOR UTILIZATION AS ORL1-RECEPTOR AND MU-OPIATE RECEPTOR LIGANDS | Grünenthal GmbH (DE) | 2004-05-27 | — | — | WO | disclosed |
| US-4447454-A | Analgetic compounds, compositions and process of treatment | THE UPJOHN COMPANY (US) | 1984-05-08 | — | — | US | disclosed |
| US-4113866-A | ANALGETIC COMPOUNDS, COMPOSITIONS AND PROCESS OF TREATMENT | THE UPJOHN COMPANY (US) | 1978-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277674-A1 | 4-substituted 1-aminocyclohexane compounds for utilization as ORL1-receptor and mu-opiate receptor ligands | OPRL1, OPRM1, OGFRL1 | OPRL1 1/4885OPRM1 2/4885OPRK1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.